secwatch.observer — SEC 8-K summary
======================================

Issuer:     Spyre Therapeutics, Inc. (SYRE)
CIK:        0001636282
Form:       8-K
Filed at:   2026-04-13T23:59:59+00:00
Accession:  0001628280-26-024906
Event type: other_material
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Spyre reports preliminary $741M cash; suspends ATM offering
-----------------------------------------------------------

- Preliminary cash, equivalents and marketable securities of $741M as of March 31, 2026.
- Includes $30M legacy asset disposition proceeds; $23M expected to be paid to CVR holders in Q2 2026.
- Effective April 13, 2026, terminated ATM prospectus; no further share sales under Sales Agreement until new filing.
- Sales Agreement with TD Securities remains in force; company funded without current need for dilution.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1636282/000162828026024906/0001628280-26-024906-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1636282/000162828026024906/syre-20260413.htm
  HTML page:      https://secwatch.observer/filing/0001628280-26-024906

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer